A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Aleix Prat, Valentina Guarneri, Laia Paré et al. · The Lancet Oncology · 2020
Cited by 80 works. doi:10.1016/s1470-2045(20)30450-2
Authors
- Aleix Prat
- Valentina Guarneri
- Laia Paré
- Gaia Griguolo
- Tomás Pascual
- Maria Vittoria Dieci
- Núria Chic
- Blanca González‐Farré
- Antonio Frassoldati
- Esther Sanfeliu
- Juan Miguel Cejalvo
- Montserrat Muñoz-Mateu
- Giancarlo Bisagni
- Fara Brasó‐Maristany
- Loredana Urso
- María Vidal
- Alba Ariela Brandes
- Bárbara Adamo
- Antonino Musolino
- Federica Miglietta
References
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial